Vernetzungsprotokoll der AML Studien im Rahmen des Kompetenznetz Akute und chronische Leukämien BMBF Version

Size: px
Start display at page:

Download "Vernetzungsprotokoll der AML Studien im Rahmen des Kompetenznetz Akute und chronische Leukämien BMBF Version 14.11.02"

Transcription

1 11 Literatur 1. Büchner T., Hiddemann W., Koenigsmann M. et al.: Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: , Büchner T., Hiddemann W., Wörmann B. et al.: Double Induction Strategy for Acute Myeloid Leukemia: The Effect of High-Dose Cytarabine with Mitoxantrone instead of Standard-Dose Cytarabine with Daunorubicin and 6-Thioguanine. A Randomized Trial by the German AML Cooperative Group. Blood 93: , Hiddemann W., Kern W., Schoch C. et al.: Management of acute myeloid leukemia in elderly patients. JCO 17: , Fenaux P., Chastang C., Chevret S., Sanz M., Dombret H., Archimbaud E., Fey M., Rayon C., Huguet F., Sotto J.J., Gardin C., Makhoul P.C., Travade P., Solary E., Fegueux N., Bordessoule D., Miguel J.S., Link H. et al.: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 94: , Lengfelder E., Reichert A., Schoch C. et al.: Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 14: , Heil G., Chadid L., Hoelzer D., Seipelt G., Mitrou P., Huber C., Kolbe K., Mertelsmann R., Lindemann A., Frisch J., Nicolay U., Gaus W., Heimpel H.: GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia, 9, 3-9, Heil G., Mitrou PS., Hoelzer D., Freund M., Link H., Ehninger G., Steinke B., Öhl S., Wandt H., Fackler-Schwalbe E., Schlimok G., Lösch A., Queißer W., Löffler B., Gaus W., Högel J., Heimpel H., Kurrle E.: High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial. Ann Hematol 71, , Heil G., Hoelzer D., Sanz MA., Lechner K., Liu Yin JA., Papa G., Noens L., Szer J., Ganser A., O'Brien C., Matcham J., Barge A.: A randomized, double-blind, placebo-controlled phase III study of filgrastim in remission induction and consolidation therapyfor adults with de novo acute myeloid leukemia. Blood, 90, , Archimbaud E., Ottmann OG., Yin JA., Lechner K., Dombret H., Sanz MA., Heil G., Fenaux P., Brugger W., Barge A., O'Brien-Ewen C., Matcham J., Hoelzer D.: A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 94, , Ganser A., Heil G., Seipelt G., Hofmann W., Fischer JT., Langer W., Brockhaus W., Kolbe K., Ittel TH., Brack N., Fuhr HG., Knuth P., Hoffken K., Bergmann L., Hoelzer D.: Intensive chemotherapy with idarubicin, ara-c, etoposide, and m-amsa followed by immunotherapy with interleukin-

2 12 2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML). Ann Hematol, 79, 30-35, Karthaus M., Doellmann T., Klimasch T., Elser C., Rosenthal C., Ganser A., Heil G.: Intensive intravenous amphotericinb for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients. Chemtherapy 46: , Wandt H., Frank M., Ehninger G., Schneider C., Brack N., Daoud A., Fackler-Schwalbe I., Fischer J., Gackle R., Geer T., Harms P., Loffler B., Ohl S., Otremba R., Raab M., Schönrock-Nabulsi P., Strobel G., Winter R., Link H.: Safety and cost effectiveness of a 10 x 10 (9) / L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10 (9) / L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91: , Ottinger HD., Albert E., Arnold R., Beelen DW., Blasczyk R., Bunjes D., Burdach S., Ebell W., Ehninger G., Einsele H., Enczmann J., Fauser A., Friedrich W., Finge J., Gobel U., Goldmann SF., Gramatzki M., Helbig W., Kanz L., Klingebiel T., Kolb HJ., Kuhnl P., Lolinger C., Müller CR., Grosse-Wilde H., et al.: German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem sells. Bone Marrow Transplant. 20: , Ringden O., Remberger M., Runde V., Bornhäuser M., Blau IW., Basara N., Holig K., Beelen DW., Haglund H., Basu O., Ehninger G., Fauser AA.: Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 94: , Bornhäuser M., Theuser C., Soucek S., Holig K., Klingebiel T., Blau W., Fauser A., Runde V., Schwinger W., Rutt C., Ehninger G.: Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis. Haemtologica 85: , Hilbe W., Thaler J., Eisterer W., Ludescher C., Niederwieser D.: Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). Leukemia Res 18: , Helbig W., Krahl R., Kubel M., Schwenke H., Herold M., Fiedler F., Franke A., Lakner V., Rohrberg R., Kämpfe D., Strohbach F., Schott G.., von Grünhagen U., Grobe N., Pasold R., Stauch M., Fleischer J., Klinkenstein C., Boewer C., Steglich J., Richter P., Pillkahn R., Subert R., Rudorf I., Eisengarten K., Morgenstern D. (East German Study Group, EGSG): Long-term results in adult AML: Comparison of postremission chemotherapy (CT) vs. autologous BMT vs. allogeneic BMT. Acute Leukemia V Experimental Approaches and Management of Refractory Disease, Hiddemann W. et al. (Eds.), Springer-Verlag Berlin Heidelberg New York, , Kolb HJ., Schattenberg A., Goldman JM., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D., van Rhee F., Mittermüller J., de Witte T., Holler E., Ansari H. for the EBMT Working Party Chronic Leukemia: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86: , Glass B., Uharek L., Zeis M., Dreger P., Loffler H., Steinmann J., Schmitz N.: Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graftversus-leukemia effect. Blood 90: , Runde V., de Witte T., Arnold R., Gratwohl A., Hermans J., van Biezen A., Niederwieser D., Labopin M., Walter-Noel MP., Bacigalupo A., Jacobsen N., Ljungman P., Carreras E., Kolb HJ.,

3 13 Aul C., Apperley J. on behalf of the Chronic Leukemia Working Party of the European Group for Bone marrow transplantation from HLA-identical siblings as first line treatment in patients with myelodysplastic syndromes or secondary acute myelogenous leukaemia: A European survey. Bone Marrow Transpl 21: , de Witte T., Hermans J., Vossen J., Bacigalupo A., Meloni G., Jacobson N., Ruutu T., Ljungman P., Gratwohl A., Runde V., Niederwieser D., van Biezen A., Devergie A., Cornelissen J., Jouet JP., Arnold R., Apperley J.: Haematopoietic stem cell transplantation in myelodysplastic syndromes and secondary acute myeloid leukemias: a report on behalf of the Chronic Leukemia Working Party of the European Blood and Marrow Transplant Group. Br J Haematol 110: , Storb R., McSweeney P., Sandaier BM., Nash RA., Georges G., Maloney DG., Molina A., Chauney T., Yu C., Zaucha M., Blume KG., Shizuru J., Niederwieser D.: Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the 21th century. Transplantation Proceedings 32: , Lehmann C., Zeis M., Schmitz N., Uharek L.: Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 96: , McSweeney PA., Niederwieser D., Shizuru J., Molina A., Chauncey TR., Gooley TA., Hegenbart U., Maloney, DG., Nash R., Sandmaier BM., Blume FK., Storb RF.: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, in Press. 25. Schoch C., Haferlach T., Haase D. et al.: Complex chromosome aberrations in patients with de novo AML are associated with a very poor prognosis despite intensive treatment: A study of 90 patients. Blood 90 Suppl 1:62a, Bishop J, Lowenthal R, Joshua D et al. Etoposide in acute nonlymphocytic leukemia. Blood 75:27-32, Dillmann R., Davis R., Green M. et al.: A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 78: , Bishop J., Matthews J., Young G. et al.: A randomized study of high-dose cytarabine induction in acute myeloid leukemia. Blood 87: , Rees J, Gray R, Wheatly K. Dose intensification in acute myeloid leukemia: greater effectiveness at lower cost. Principal report of the Medical Research Councils s AML9 study. Br J Haematol 94:89-98, Cassileth P, Lynch E., Hines J. et al.: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79, , Mayer R.J., Davis R.B., Schiffer C.A. et al.: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331: , 1994.

4 Zittoun R.A., Mandelli F., Willemze R. et al.: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl. J. Med. 332: , Weick J., Kopecky K., Appelbaum F. et al.: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. Blood 88: , Burnett A., Goldstone A., Stevens R. et al.: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 351: , Cassileth P., Harrington D., Appelbaum F. et al.: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New Engl. J. Med. 339: , Byrd J., Dodge R., Carroll A. et al.: Patients with t(8;21) (q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. JCO 17: , Bennett J.M., Catovsky D., Daniel M.T. et al., the Frech-American-British (FAB) Cooperative Group: Proposals for the classification of the acute leukemias. Brit. J. Haematol. 33:451, Bennett J.M., Catovsky D., Daniel M.T. et al., the French-American-British (FAB) Cooperative Group: Proposals for the classification of the myelodysplastic syndromes. Brit. J. Haematol. 51:189, Bennett J.M., Catovsky D., Daniel M.T. et al.: Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Annals Intern. Med. 103:460, Bennett J.M., Catovsky D., Daniel M.T. et al.: Proposed Revised Criteria for the Classification of Acute Myeloid Leukemia. Ann. Intern. Med. 103:626, Cheson B.D., Cassileth P.A., Head D.R. et al.: Report of the National Cancer Institute-Sponsored workshop on definition of diagnosis and response in acute myeloid leukemia. J.Clin. Oncol. 8:813, Harris N., Jaffe E., Diebold J. et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting Airlie House, Virginia, November JCO 17: , Fischer K., Scholl C., Salat J. et al.: Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. Blood 88: , Fischer K., Fröhling S., Scherer S. et al.: Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemia. Blood 89: , Döhner K., Brown J., Hehmann U. et al.: Molecular cytogenetic characterization of critical region in band 7135-q36 commonly deleted in malignant myeloid disorders. Blood 92: , 1998.

5 Haase D., Feuring-Buske M., Könemann S. et al.: Evidence of malignant transformation in acute myeloid leukemia at the Level of early hematopoietic stem cells by cytogenetic analysis of CD34 + Subpopulation. Blood 86: , Haferlach T., Winkemann M., Löffler H. et al.: The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: A combination of May-Grünwald-Giemsa staining and fluorescence in situ hypridization. Blood 87: , Schoch C., Haase D., Haferlach T. et al.: Fifty-one patients with acute myeloid leukemia and translocation t(8;21) (q22;qq22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 10: , Schoch C., Haase D., Haferlach T. et al.: Incidence and implication of additional chromosome aberrations in acute promyelocytic leukemia with translocation t(15;17) (q22;q21): a report on 50 patients. Br J Haematol 94: , Schoch C., Haase D., Fonatsch C. et al.: The significance of trisomy 8 in de novo acute myeloid leukemia: the accompanying chromosome aberrations determine the prognosis. Br J Haematol 99: , Streubel B., Sauerland C., Heil G. et al.: Correlation of cytogenetic, molecular cytogenetic, and clinical findings in 59 patients with ANLL or MDS and abnormalities of the short arm of chromosome 12. Br J Haematol 100: , Streubel B., Valent P., Jäger U. et al.: Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. Genes, Chromosomes & Cancer 27: , Schnittger S., Wörmann B., Hiddemann W. et al.: Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood 92: , Dreyling M., Schrader K., Fonatsch C. et al.: MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): Both rearrangements are associated with a poor prognosis. Blood 91: , Mizuki M., Fenski R., Halfter H. et al.: Flt3 mutations from AML patients induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96: , Müller C., Yang R., Park D. et al.: The aberrant fusion proteins PML-RARα and PLZF-RARα contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia. Blood 96: , Heil G., Gunsilius E., Raghavachar A., Bartram C., Ganser A., Kurrle E., Aydemir Ü., Löffler H., Hoelzer D., Thiel E., Heimpel H.: Ultrastructural demonstration of peroxidase expression in acute unclassified leukemias: correlation to immunophenotype and treatment outcome. Blood, 6, , Krauter J., Peter W., Pascheberg U., Heinze B., Bergmann L., Hoelzer D., Lübbert M., Schlimok G., Arnold R., Kirchner H., Port M., Ganser A., Heil G.: Detection of karyotypic aberrations in

6 16 acute myeloblastic leukemia: A prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. Br J Haematol, 103, 72-78, Krauter J., Ganser A., Bergmann L., Raghavachar A., Hoelzer D., Lübbert M., Schlimok G., Arnold R., Kirchner H., Port M., Heil G.: Association between structural and numerical chromosomal aberrations in acute myeloblastic leukemia: a study by RT-PCR and FISH in 447 patients with denovo AML. Ann Hematol, 78, , Krauter J., Wattjes MP., Nagel S., Heidenreich O., Krug U., Kafert S., Bunjes D., Bergmann L., Ganser A., Heil G.: Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. Br J Haematol, 107, 80-85, Krauter J., Hoellge W., Wattjes MP., Nagel S., Heidenreich O., Bunjes D., Ganser A., Heil G.: Detection and quantification of CBFb/MYH11 fusion transcripts in patients with inv(16) positive acute myeloblastic leukemia by real time RT-PCR. Genes Chromosomes Cancer 2001, im Druck 62. Beck J., Handgretinger R., Klingebiel T., Dopfer R., Schaich M., Ehninger G., Niethammer D., Gekeler V.: Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia 10: , Ritter M., Thiede C., Schakel U., Schmidt M., Alpen B., Pascheberg U., Mohr B., Ehninger G., Neubauer A.: Underestimation of inversion (16) in acute myeloid leukemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation. Br J Haematol 98: , Illmer T., Schaich M., Oelschlagel U., Nowak R., Renner U., Ziegs B., Subat S., Neubauer A., Ehninger G.: A new PCR MIMIC strategy to quantify low mdt1 mrna levels in drug resistant cell lines and AML blast samples. Leuk Res. 23: , Mohr B., Bornhäuser M., Thiede C., Schakel U., Schaich M., Illmer T., Pascheberg U., Ehninger G.: Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia 14: , Dupont W.D., Plummer W.D.: Power and Sample Size Calculations: A Review and Computer Program. Controlled Clin Trials 11: , <www.mc.vanderbilt.edu/prevmed/p.s.htm> 1/ O'Brien P.C., Fleming T.R. A Multiple Testing Procedure for Clinical Trials. Biometrics 35: , Hasford J., Baccarani M., Hehlmann R., Ansari H., Tura S., Zuffa E. Interferon-α and Hydroxyurea in Early Chronic Myeloid Leukemia: A Comparative Analysis of the Italian and German Chronic Myeloid Leukemia Trials With Interferon-α. Blood 87, , CML Trialists' Collaborative Group. Interferon-alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Nat Cancer Inst 89, , Gale R., Hehlmann R., Zhang M.-J., Hasford J., Goldman J., Heimpel M..et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia (CML). Blood 91, , 1998.

7 Hasford J., Pfirrmann M., Hehlmann R., Allan N.C., Baccarani M., Kluin-Nelemans J. A. New Prognostic Score for Survival of Patients with Chronic Myeloid Leukemia Treated with Interferon Alfa. J Nat Cancer Inst 90: , Hehlmann R., Hochhaus A., Kolb H.-J., Hasford J., Gratwohl A., Heimpel H. et al. Interferon α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at leat 90 days before the procedure. Blood 94: , 1999.

Acute Myeloid Leukemia in Adults: Is Postconsolidation Maintenance Therapy Necessary?

Acute Myeloid Leukemia in Adults: Is Postconsolidation Maintenance Therapy Necessary? Progress in Hematology International Journal of HEMATOLOGY Acute Myeloid Leukemia in Adults: Is Postconsolidation Maintenance Therapy Necessary? Thomas Büchner, a, * Wolfgang Hiddemann, b Bernhard Wörmann,

More information

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In

More information

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)

More information

Synopsis of Causation. Chronic Myeloid Leukaemia

Synopsis of Causation. Chronic Myeloid Leukaemia Ministry of Defence Synopsis of Causation Chronic Myeloid Leukaemia Author: Dr M A Vickers, University of Aberdeen, Aberdeen Validator: Professor John Goldman, Hammersmith Hospital, London September 2008

More information

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including

More information

Biometrische Aspekte der Studien zur akuten myeloischen Leukämie: Sequentielle Verfahren und Evaluation prognostischer Faktoren

Biometrische Aspekte der Studien zur akuten myeloischen Leukämie: Sequentielle Verfahren und Evaluation prognostischer Faktoren Biometrische Aspekte der Studien zur akuten myeloischen Leukämie: Sequentielle Verfahren und Evaluation prognostischer Faktoren Dipl.-Math. C. Sauerland (sauerla@uni-muenster.de) Dipl.-Biomath. S. Amler

More information

Treating Minimal Residual Disease in Acute Leukemias: How low should you go?

Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and

More information

Ar Mino changes including adjustment of therapy algorithms

Ar Mino changes including adjustment of therapy algorithms cute Myeloid Leukemia Updated April 2008 by Dr. Richard Wells* Updates: Ar Mino changes including adjustment of therapy algorithms Introduction Acute myeloid leukemia is a relatively uncommon cancer with

More information

Acute myeloid leukemia (AML)

Acute myeloid leukemia (AML) Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult

More information

Curative treatment in acute myeloid leukemia (AML)

Curative treatment in acute myeloid leukemia (AML) ACUTE MYELOID LEUKEMIA Optimal induction and post-remission therapy for AML in first remission Jacob M. Rowe 1 1 Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion,

More information

Relative Risk (Sokal & Hasford): Relationship with Treatment Results. Michele Baccarani

Relative Risk (Sokal & Hasford): Relationship with Treatment Results. Michele Baccarani Relative Risk (Sokal & Hasford): Relationship with Treatment Results Michele Baccarani European LeukemiaNet EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA VENICE 8 9 MAY 2006 Disease risk

More information

MEDICAL COVERAGE POLICY

MEDICAL COVERAGE POLICY Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each

More information

Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012

Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology

More information

Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma

Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Updated April 2008 by Dr. Richard Wells* Updates: Minor changes only Introduction Acute lymphocytic leukemia (ALL) is a relatively

More information

APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen

APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen Outline Diagnosis Prognosis Treatment AML Elderly AML APL Future directions AML

More information

Therapeutic Options in the Management of Acute Myelogenous Leukemia in Adults

Therapeutic Options in the Management of Acute Myelogenous Leukemia in Adults Therapeutic Options in the Management of Acute Myelogenous Leukemia in Adults Ruben A. Saez, MD Several advances in evaluation and treatment have improved the prognosis of adults with acute myelogenous

More information

Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Stem Cell Transplantation for Acute Lymphoblastic Leukemia Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic

More information

Cytogenetic Profile of Monosomal Karyotype in Adult Acute Myeloid Leukemia

Cytogenetic Profile of Monosomal Karyotype in Adult Acute Myeloid Leukemia International Journal of Scientific and Research Publications, Volume 3, Issue 11, November 2013 1 Cytogenetic Profile of Monosomal Karyotype in Adult Acute Myeloid Leukemia Yuet-Meng Chin, Puteri J Noor,

More information

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group VOLUME 27 NUMBER 1 JANUARY 1 29 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T From the Departments of Hematology and Oncology and Medical Informatics and Biomathematics, University of Münster,

More information

Risk Stratification in AML. Michelle Geddes Feb 27, 2014

Risk Stratification in AML. Michelle Geddes Feb 27, 2014 Risk Stratification in AML Michelle Geddes Feb 27, 2014 Objectives Outline the challenges in post-remission therapy for AML Review etiology of disease escape mechanisms from therapy Evaluate prognostic

More information

CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More

CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,

More information

Cytarabine Dose for Acute Myeloid Leukemia

Cytarabine Dose for Acute Myeloid Leukemia original article Cytarabine Dose for Acute Myeloid Leukemia Bob Löwenberg, M.D., Thomas Pabst, M.D., Edo Vellenga, M.D., Wim van Putten, M.Sc., Harry C. Schouten, M.D., Carlos Graux, M.D., Augustin Ferrant,

More information

C 5-AZ 300 mg/m2 (I") 64.5. Targeted Plasma Drug Concentration: A New Therapeutic Approach to Relapsed Nonlymphoblastic Leukemia in Children*

C 5-AZ 300 mg/m2 (I) 64.5. Targeted Plasma Drug Concentration: A New Therapeutic Approach to Relapsed Nonlymphoblastic Leukemia in Children* Targeted Plasma Drug Concentration: A New Therapeutic Approach to Relapsed Nonlymphoblastic Leukemia in Children* J. Mirro Jr. I, W.R. Crom 2, D.K. Kalwinsky V.M. Santana I, D.K. Baker 2, and J. Belt A.

More information

AML: How to characterize and treat elderly patients non fit for standard chemotherapy

AML: How to characterize and treat elderly patients non fit for standard chemotherapy m1 AML: How to characterize and treat elderly patients non fit for standard chemotherapy Clinic for Medicine III University Hospital Munich Campus Grosshadern AMLCG study group Karsten Spiekermann, MD

More information

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Nicolaus Kröger, Ronald Brand, Anja Van Biezen, Axel Zander, Judith

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib

More information

A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly

A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly Clinical Therapeutics/Volume 33, Number 3, 2011 A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly Dimitrios C. Ziogas, MD 1,2 ; Michael

More information

Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia

Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Dr Jordi Sierra Gil IRHSP Institut de Recerca Hospital de la Santa Creu i Sant Pau Dr. Miguel Ángel Sanz Alonso Fundación

More information

EBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 356 CHAPTER 20. HSCT for acute myeloid leukaemia in adults. R. Varaldo, F. Frassoni

EBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 356 CHAPTER 20. HSCT for acute myeloid leukaemia in adults. R. Varaldo, F. Frassoni EBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 356 * CHAPTER 20 HSCT for acute myeloid leukaemia in adults R. Varaldo, F. Frassoni EBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 357 CHAPTER 20 AML in adults

More information

Acute Myeloid Leukemia: The Challenge of Unfavorable Cytogenetics

Acute Myeloid Leukemia: The Challenge of Unfavorable Cytogenetics Acute Myeloid Leukemia: The Challenge of Unfavorable Cytogenetics August 03, 2012 By Gordana Raca, MD [1] and Richard A. Larson, MD [2] Prognostic factors in acute myeloid leukemia (AML) may be subdivided

More information

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

Cancer. 9p21.3 deletion. t(12;21) t(15;17) CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)

More information

Stem Cell Transplantation

Stem Cell Transplantation Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

Therapy-related leukemia/myelodysplastic syndrome in multiple myeloma

Therapy-related leukemia/myelodysplastic syndrome in multiple myeloma Therapy-related leukemia/myelodysplastic syndrome in multiple myeloma KAZUHIKO NATORI DAISUK NAGASE SUSUMU ISHIHARA AKIKO YUKITOSHI TOYODA MOTOHIRO KATO YOSINORI FUJIMOTO YASUNOBU KURAISHI HARUKA IZUMI

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time

Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in

More information

What is a Stem Cell Transplantation?

What is a Stem Cell Transplantation? What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am

More information

Treatment of the elderly patient with acute myeloid leukaemia

Treatment of the elderly patient with acute myeloid leukaemia 8 Treatment of the elderly patient with acute myeloid leukaemia BOB LOWENBERG Acute myeloid leukaemia (AML) is seen at all ages, but more than half of the patients with AML are 60 years of age or older

More information

Protocol. Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia

Protocol. Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia Hematopoietic Stem-Cell Transplantation for Acute Myeloid (80126) Medical Benefit Effective Date: 07/01/14 Next Review Date: 05/16 Preauthorization Yes Review Dates: 04/07, 05/08, 05/09, 05/10, 05/11,

More information

Clinical Use of Karyotype and Molecular Markers In Curing Acute Myeloid Leukemia

Clinical Use of Karyotype and Molecular Markers In Curing Acute Myeloid Leukemia Clinical Use of Karyotype and Molecular Markers In Curing Acute Myeloid Leukemia Clara D. Bloomfield, M.D. Distinguished University Professor The Ohio State University Comprehensive Cancer Center, and

More information

Hematologic Malignancies

Hematologic Malignancies Hematologic Malignancies Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan

More information

Acute Myelogenous Leukemia: A Guide for Patients and Caregivers

Acute Myelogenous Leukemia: A Guide for Patients and Caregivers Acute Myelogenous Leukemia: A Guide for Patients and Caregivers LE UK E M I A Printing of this publication made possible by an education grant from LYMPHOMA M Y E L OM A Introduction Table of Contents

More information

Extramedullary Infiltration at Diagnosis and Prognosis in Children With Acute Myelogenous Leukemia

Extramedullary Infiltration at Diagnosis and Prognosis in Children With Acute Myelogenous Leukemia Pediatr Blood Cancer 2007;48:393 398 Extramedullary Infiltration at Diagnosis and Prognosis in Children With Acute Myelogenous Leukemia Ryoji Kobayashi, MD, 1 * Akio Tawa, MD, 2 Ryoji Hanada, MD, 3 Keizo

More information

Published Ahead of Print on May 31, 2011 as 10.1200/JCO.2010.32.8500. J Clin Oncol 29. 2011 by American Society of Clinical Oncology INTRODUCTION

Published Ahead of Print on May 31, 2011 as 10.1200/JCO.2010.32.8500. J Clin Oncol 29. 2011 by American Society of Clinical Oncology INTRODUCTION Published Ahead of Print on May 31, 11 as 1.1/JCO.1.32.85 The latest version is at http://jco.ascopubs.org/cgi/doi/1.1/jco.1.32.85 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term Prognosis

More information

CANCER TREATMENT PATHWAYS: AML A DETAILED COSTING STUDY EXAMPLE HAN-I WANG. PhD

CANCER TREATMENT PATHWAYS: AML A DETAILED COSTING STUDY EXAMPLE HAN-I WANG. PhD CANCER TREATMENT PATHWAYS: AML A DETAILED COSTING STUDY EXAMPLE HAN-I WANG PhD 2010 CANCER TREATMENT PATHWAYS: AML A DETAILED COSTING STUDY EXAMPLE HAN-I WANG Submitted for the degree of Doctor of Philosophy

More information

Cytogenetics for the Rest of Us: A Primer

Cytogenetics for the Rest of Us: A Primer Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen

More information

Survival from acute non-lymphocytic leukaemia, 1971-88: a population based study

Survival from acute non-lymphocytic leukaemia, 1971-88: a population based study Archives of Disease in Childhood 1994; 70: 219-223 Survival from acute non-lymphocytic leukaemia, 1971-88: a population based study 219 C A Stiller, E M Eatock Childhood Cancer Research Group, University

More information

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods

More information

Acute Myeloid Leukemia Research Paper

Acute Myeloid Leukemia Research Paper Acute Myeloid Leukemia Research Paper [haematologica] 24;89:48-418 A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German

More information

Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies

Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies Robert J. Arceci, M.D., Ph.D. King Fahd Professor of Pediatric Oncology Professor of Pediatrics, Oncology and

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015 LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:

More information

Acute leukemias and myeloproliferative neoplasms

Acute leukemias and myeloproliferative neoplasms Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

Autologous stem cell transplantation with moderate dose of Idarubicin and Busulphan as conditioning regimen in acute myelogenous leukemia

Autologous stem cell transplantation with moderate dose of Idarubicin and Busulphan as conditioning regimen in acute myelogenous leukemia Iranian Red Crescent Medical Journal Autologous stem cell transplantation with moderate dose of Idarubicin and Busulphan as conditioning regimen in acute myelogenous leukemia ORIGINAL ARTICLE MA Mashhadi

More information

Pan Birmingham Cancer Network: Haematology NSSG Chemotherapy Regimens AML intensive v1.0 August 2010

Pan Birmingham Cancer Network: Haematology NSSG Chemotherapy Regimens AML intensive v1.0 August 2010 AML - TRIALS It is best practise for all patients to be treated on the appropriate NCRI national trial for AML. It is outside of the remit for this regimen list to provide a comprehensive detail of the

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

Management of Acute Myelogenous Leukemia in the Elderly

Management of Acute Myelogenous Leukemia in the Elderly Treatment regimens for acute myelogenous leukemia should be based on biologic and prognostic factors rather than on patient age. Paul Gauguin. Still Life with Onions, Beetroot and a Japanese Print, 1889.

More information

Acute Myeloid Leukemia

Acute Myeloid Leukemia Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,

More information

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Hagop M. Kantarjian, MD Chairman, Leukemia Department Department of Hematology

More information

Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation

Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation Dr Ros Ganderton, Ms Kate Parratt, Dr Debbie Richardson, Dr Kim Orchard and Dr Liz Hodges Departments of Molecular Pathology

More information

in silico hematology

in silico hematology in silico hematology Application of mathematical modeling to predict the outcome of leukemia treatment by Ingmar Glauche and Ingo Röder Chronic Myeloid Leukemia (CML) accounts for about 20 % of all leukemias

More information

The evolving role of stem cell transplantation in acute promyelocytic leukemia

The evolving role of stem cell transplantation in acute promyelocytic leukemia The evolving role of stem cell transplantation in acute promyelocytic leukemia 1 S.M. Ramadan, 2 L. Cicconi, 1, 3 F. Lo-Coco I Simposio Conjunto EHA - SAH 1Department of Biomedicine and Prevention, University

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information

Perspectives on the Treatment of Acute Myeloid Leukemia

Perspectives on the Treatment of Acute Myeloid Leukemia Perspectives on the Treatment of Acute Myeloid Leukemia LORI J. MANESS, MD Assistant Professor of Medicine University of Nebraska Medical Center College of Medicine Section of Oncology/Hematology Omaha,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll

More information

Treatment of acute myeloid leukemia: are we making progress?

Treatment of acute myeloid leukemia: are we making progress? HAM-WASSERMAN LECTURE Treatment of acute myeloid leukemia: are we making progress? Alan K. Burnett 1 1 School of Medicine, Cardiff University, Cardiff, United Kingdom With a few subgroups as exceptions,

More information

Acute Myeloid Leukemia

Acute Myeloid Leukemia Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not

More information

Cytogenetic Testing in Acute Leukemia. June 4, 2009

Cytogenetic Testing in Acute Leukemia. June 4, 2009 Cytogenetic Testing in Acute Leukemia June 4, 2009 Objectives Describe genetic aspects of the 2008 WHO classification of acute leukemia Understand cytogenetic and molecular cytogenetic techniques Understand

More information

Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.

Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand. 1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow

More information

The AML Guide. Information for Patients and Caregivers. Acute Myeloid Leukemia. Emily, AML survivor

The AML Guide. Information for Patients and Caregivers. Acute Myeloid Leukemia. Emily, AML survivor The AML Guide Information for Patients and Caregivers Acute Myeloid Leukemia Emily, AML survivor Revised 2012 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society

More information

For further advice contact the clinical information team on 020 7269 9060.

For further advice contact the clinical information team on 020 7269 9060. Revised June 2011 The diagnosis of a blood cancer can be a devastating event for patients, families and friends. It is therefore vital for everyone to have access to reputable and understandable information

More information

Acute myeloid leukaemia (AML) in children

Acute myeloid leukaemia (AML) in children 1 61.02 Acute myeloid leukaemia (AML) in children AML can affect children of any age, and girls and boys are equally affected. Leukaemia Acute myeloid leukaemia (AML) FAB classification of AML Causes of

More information

Acute Myeloid Leukemia Therapeutics Market to 2020

Acute Myeloid Leukemia Therapeutics Market to 2020 Brochure More information from http://www.researchandmarkets.com/reports/3030124/ Acute Myeloid Leukemia Therapeutics Market to 2020 Description: Summary: Treatment and prognosis in AML is strongly influenced

More information

LEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova

LEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova LEUCEMIA MIELOIDE ACUTA A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova Impact of mutational analysis in AML C. Thiede Optimal acute myeloid leukemia therapy in 2012 H. Dombret Acquired

More information

Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer

Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_breast_cancer

More information

Project Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D

Project Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:

More information

STUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan

STUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan STUDY PROTOCOL Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly

More information

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Clinical Development Program Prof. Moshe Phillip, MD VP Clinical & Medical Affairs 1 Rationale for BL-8040 Development

More information

REVIEW DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA

REVIEW DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA SCRIPTA MEDICA (BRNO) 73 (4): 223 228, October 2000 REVIEW DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA MICHÁLEK J. 1, MARDA J. 2 1 First Department of Paediatrics, Mendel Memorial Children

More information

Medical Policy Manual. Date of Origin: May 2010. Topic: Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia

Medical Policy Manual. Date of Origin: May 2010. Topic: Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia Medical Policy Manual Topic: Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia Section: Transplant Policy No: 45.28 Date of Origin: May 2010 Last Reviewed Date: January 2015 Effective

More information

Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia PATIENT RESOURCE CANCER GUIDE Acute Promyelocytic Leukemia Take Control Phases of Treatment Available Resources & Clinical Trial Research Reviewed by a Distinguished Medical Advisory Board PatientResource.com

More information

Developments and Quality Assurance in Stem Cell Transplantation

Developments and Quality Assurance in Stem Cell Transplantation This text is a translation from the original German which should be used for referencing. The German version is authoritative. ORIGINAL ARTICLE Developments and Quality Assurance in Stem Cell Transplantation

More information

DESCRIPTION/BACKGROUND

DESCRIPTION/BACKGROUND Original Issue Date (Created): August 23, 2004 Most Recent Review Date (Revised): Effective Date: October 21, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND Hematopoietic Stem-Cell Transplantation

More information

ACUTE MYELOID LEUKEMIA (AML),

ACUTE MYELOID LEUKEMIA (AML), 1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly

More information

The CML Guide Information for Patients and Caregivers

The CML Guide Information for Patients and Caregivers The CML Guide Information for Patients and Caregivers LEUKEMIA LYMPHOMA CHRONIC MYELOGENOUS LEUKEMIA MYELOMA Printing of this publication made possible by a grant from A Message from John Walter President

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia

More information

Selecting an appropriately matched donor for hematopoietic

Selecting an appropriately matched donor for hematopoietic Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation

More information

Oncologist. The. Pediatric Oncology. Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia

Oncologist. The. Pediatric Oncology. Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia The Oncologist Pediatric Oncology Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia SOHEIL MESHINCHI, a ROBERT J. ARCECI b a Fred Hutchinson Cancer Research Center, University

More information

Cost and Outcome of Treatment of Adults with Acute Myeloid Leukemia at the National Cancer Institute-Egypt

Cost and Outcome of Treatment of Adults with Acute Myeloid Leukemia at the National Cancer Institute-Egypt Journal of the Egyptian Nat. Cancer Inst., Vol. 19, No. 2, June: 106-113, 2007 Cost and Outcome of Treatment of Adults with Acute Myeloid Leukemia at the National Cancer Institute-Egypt HEBA M. EL-ZAWAHRY,

More information

Stem Cell Transplantation in Adults

Stem Cell Transplantation in Adults Recommendation Report Stem Cell Transplantation in Adults K. Imrie, R.B. Rumble, M. Crump, the Advisory Panel on Bone Marrow and Stem Cell Transplantation, and the Hematology Disease Site Group of Cancer

More information

Response Definition, Evaluation and Monitoring. Michele Baccarani

Response Definition, Evaluation and Monitoring. Michele Baccarani Response Definition, Evaluation and Monitoring Michele Baccarani European LeukemiaNet EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA VENICE 8 9 MAY 2006 Response definition, evaluation

More information

Other treatments for chronic myeloid leukaemia

Other treatments for chronic myeloid leukaemia Other treatments for chronic myeloid leukaemia This information is an extract from the booklet Understanding chronic myeloid leukaemia. You may find the full booklet helpful. We can send you a copy free

More information

Myeloablative conditioning regimens for the

Myeloablative conditioning regimens for the ACUTE MYELOID LEUKEMIA What is the role of reduced-intensity transplantation in the treatment of older patients with AML? Stephen J. Forman 1 1 Department of Hematology and Hematopoietic Cell Transplantation,

More information

How High Can We Increase Complete Remission Rate in Adult Acute Myeloid Leukemia?

How High Can We Increase Complete Remission Rate in Adult Acute Myeloid Leukemia? Progress in Hematology International Journal of HEMATOLOGY How High Can We Increase Complete Remission Rate in Adult Acute Myeloid Leukemia? Ryuzo Ohno Aichi Cancer Center, Nagoya, Japan Received August

More information

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several Track 3: Goals of therapy I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several factors she ll use to decide what s best for me. Let s talk about making treatment

More information